Autologous Mesenchymal Stem Cells to Provide Immune Support Against COVID-19

HOUSTON, April 6, 2020 — Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19.

MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation. In COVID-19 patients, inflammation is a driving force behind disease progression, and it is critical to regulate the immune system as early as possible. [Read more…]

TORONTO, ON – April 6th, 2020—INTELLiSTEM Technologies Inc, a biotechnology company pioneering cellular vaccines and peptide therapeutics, announced the successful development of a peptide-based vaccine (IPT-001) intended for human use against COVID-19.

IPT-001 is a peptide-based vaccine developed using the novel coronavirus COVID-19. It was engineered using INTELLiPEPTIDOME^™ Platform to target both the Spike (S) and Nucleocapsid (N) proteins. [Read more…]

ORLANDO, Florida, March 31st, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered manufacturing facility specialized in the development and manufacturing of cell-based therapies, is pleased to announce that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA and Pre-CTA (Clinical Trial Application) with Health Canada. A complete briefing package accompanied the meeting requests. This initiates formal communications between Aspire and both the U.S. FDA and Health Canada regarding development of the Company’s cellular therapy, ACT-20 for the treatment of severe COVID-19 Pneumonia. [Read more…]

Coronavirus disease (COVID-19) is a global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019, and by March 2020, it had spread to at least 180 countries and territories worldwide. [Read more…]